Disclosure Of Material Accounting Policy Information [Text Block]

OSE Immunotherapeutics - Filing #5980970

Concept 2024-01-01 to
2024-12-31
Disclosure of material accounting policy information [text block]
ABLES
Description of accounting policy for earnings per share [text block]
t
Description of accounting policy for financial assets [text block]
4
Description of accounting policy for financial liabilities [text block]
3.13 Passifs
Description of accounting policy for foreign currency translation [text block]
4
Description of accounting policy for government grants [text block]
3.14 Aides
Description of accounting policy for impairment of assets [text block]
4
Description of accounting policy for income tax [text block]
3.18 Impôt
Description of accounting policy for leases [text block]
3.17 Contrats
Description of accounting policy for intangible assets other than goodwill [text block]
4
Description of accounting policy for provisions [text block]
3.15 Provisions
Description of accounting policy for recognition of revenue [text block]
3
Description of accounting policy for segment reporting [text block]
n
Description of accounting policy for share-based payment transactions [text block]
s
Description of accounting policy for treasury shares [text block]
3.11 Actions

Talk to a Data Expert

Have a question? We'll get back to you promptly.